US 12,139,470 B2
Trioxolane agents
Adam Robert Renslo, Oakland, CA (US); Brian Richard Blank, Daly City, CA (US); Ryan Keith Muir, Colma, CA (US); Michael John Evans, South San Francisco, CA (US); and Poulami Talukder, Cambridge, MA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Feb. 25, 2022, as Appl. No. 17/680,825.
Application 17/680,825 is a continuation of application No. 17/351,001, filed on Jun. 17, 2021, abandoned.
Application 17/351,001 is a continuation of application No. 16/625,237, granted, now 11,072,594, issued on Jul. 27, 2021, previously published as PCT/US2018/039768, filed on Jun. 27, 2018.
Claims priority of provisional application 62/525,517, filed on Jun. 27, 2017.
Prior Publication US 2022/0411396 A1, Dec. 29, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 323/02 (2006.01); A61K 31/341 (2006.01); A61K 31/351 (2006.01); A61K 31/357 (2006.01); A61K 31/496 (2006.01); A61K 31/5355 (2006.01); A61K 31/553 (2006.01); A61P 33/06 (2006.01); C07D 405/12 (2006.01); C07D 407/12 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01)
CPC C07D 323/02 (2013.01) [A61P 33/06 (2018.01); C07D 405/12 (2013.01); C07D 407/12 (2013.01); C07D 413/12 (2013.01)] 4 Claims
 
1. A compound having the formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.